AUTHORS
Pier Luigi Zinzani, MD, PhD, Enrico Derenzini, MD, PhD2, Guido Gini, MD3, Andrea Bernardelli4, Eliana Liardo5, Piero Maria Stefani6, Caterina Patti, MD7, Marco Rossi, MD, PhD8, Mario Lapecorella9, Nicola Battaglia, MS10, Carlo Visco, MD11, Antonio Pinto, MD12
AFFILIATIONS
1 Institute of Hematology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
2 IRCCS Istituto Europeo di Oncologia (IEO), Milan, Italy
3 Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy
4 UOC di Ematologia e CTMO, DAI Medico Generale, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
5 IRST IRCCS – Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
6 Ca’Foncello General Hospital, Treviso, Italy
7 Ospedale Villa Sofia-Cervello, Palermo, Italy
8 AOU R Dulbecco, Catanzaro, Italy
9 Incyte Biosciences Italy S.R.L., Milan, Italy
10 Incyte Biosciences Italy S.R.L., Milan, Italy
11 Section of Hematology, University of Verona, Verona, Italy
12 Istituto Nazionale Tumori-IRCCS-Fondazione “G. Pascale”, 80131, Napoli, Italy
ABSTRACT
Introduction: Tafasitamab plus lenalidomide (tafa-len) is an established treatment option for patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) ineligible for autologous stem cell transplantation (ASCT). Len dose reductions are common in real-world practice to manage adverse events in pts treated with this combination, leading to potential loss of treatment effectiveness. However, the impact of len relative dose intensity (RDI) reduction during early treatment on response or survival outcomes remains unknown. In the PRO-MIND study, we prospectively characterized, for the first time in a real-world setting, the association between early len RDI and subsequent outcomes in pts treated with tafa-len, adopting a landmark approach to negate early progression as a confounding factor.
Methods: PRO-MIND is an ongoing prospective, observational study enrolling ASCT-ineligible pts with R/R DLBCL treated with tafa-len in clinical practice across 28 Italian centers. Pts were stratified based on len RDI during the first 3 months (≥80% vs <80%). Objective response rate (ORR) was defined as complete response (CR) or partial response according to the Lugano 2014 criteria (when positron emission tomography/computed tomography [CT] was available) or CT-based local imaging standards. Progression-free survival (PFS) was evaluated using a 90-day landmark to avoid immortal time bias, thereby restricting the analysis to include only pts alive and progression free at 3 months. Kaplan-Meier (KM) estimates were generated by RDI group. As visual inspection of KM analysis suggested nonproportional hazards with partial crossing of survival curves, restricted mean survival time (RMST) from the 90-day landmark to 12 months was used as a complementary measure, aligned with the planned 12-cycle len duration. Adjusted RMST was estimated using pseudo-observation regression with baseline European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) summary score as a covariate. As a sensitivity analysis, a time-dependent Cox model was fitted with len RDI updated longitudinally across cycles.
Results: This analysis included 140 adult pts with median age of 78 years (range, 59, 90). Overall, 92% of pts had ≥1 comorbidity, 75% were treated in the second line, and 59% had primary refractory disease. Eastern Cooperative Oncology Group performance status was 0 in 50% of pts, 1 in 37%, and ≥2 in 13%. Baseline characteristics were balanced between RDI groups; multivariable adjustment was limited given the low event count. Response was assessed in 78 evaluable pts (RDI ≥80%, n=41; RDI <80%, n=37) and landmark PFS in 82 pts (RDI ≥80%, n=39; RDI <80%, n=43) who were progression-free at 3 months (non-nested populations). ORR was similar between the RDI ≥80% and <80% groups (73% vs 68%, Fisher’s exact P=0.626; CR rate: 44% vs 46%, P=1.000). No significant difference was observed in progression or death, which occurred in 14/39 (36%) pts with RDI ≥80% vs 10/43 (23%) pts with RDI <80% (P=0.311). KM estimate of PFS at 12 months was 57% (95% CI: 37, 76) vs 78% (95% CI: 64, 91), and at 18 months was 50% (95% CI: 30, 71) vs 66% (95% CI: 47, 85), in the RDI ≥80% and <80% groups, respectively (HR, 0.61; 95% CI: 0.27, 1.38; log-rank P=0.225). Median PFS was not estimable in either group. RMST from landmark to 12 months was 6.75 months vs 7.86 months (+1.12 months in favor of RDI <80%; P=0.126). After adjustment for baseline EORTC QLQ-C30 summary score, adjusted RMST at 12 months was 6.46 months vs 7.78 months (+1.32 months in favor of RDI <80%; P=0.090). In the time-dependent Cox model, no significant association between RDI and PFS was observed (HR, 0.75; 95% CI: 0.46,1.25; P=0.274).
Conclusions: In this exploratory real-world landmark analysis in pts with R/R DLBCL treated with tafa-len, early len RDI <80% was not associated with lower ORR, lower CR, or worse post-landmark PFS, indicating comparable disease control with early len RDI ≥80%. These findings support dose adjustment of len rather than discontinuation to mitigate tolerability issues but should not be interpreted as evidence that len dose intensity is not important. Additionally, the longer PFS observed in the RDI <80% cohort does not represent a benefit of reduced exposure due to wide confidence intervals and the analysis being underpowered. These results are hypothesis generating and warrant further validation using larger datasets.
DISCLOSURES
Pier Luigi Zinzani, MD, PhD: Roche - Honoraria; Recordati - Honoraria; Recordati - Honoraria; Novartis - Honoraria; Kyowa Kirin - Honoraria; Bristol Myers Squibb - Honoraria; MSD - Honoraria; Abbvie - Honoraria; Janssen-Cilag - Honoraria; ADC Therapeutics - Honoraria; AstraZeneca - Honoraria; Takeda - Honoraria; Sobi - Honoraria; BMS - Honoraria; Kite-Gilead - Honoraria; BeiGene - Honoraria; Abbvie - Research Funding; Secura Bio, Recordati, Kite Gilead, Janssen-Cilag, Bristol Myers Squibb, Sobi, Sandoz, MSD, Regeneron, Takeda, Roche, AstraZeneca, Kyowa Kirin, Novartis, ADC Therapeutics, Incyte, BeOne, Eli Lilly - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Kite-Gilead - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Sandoz - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Incyte Corporation - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); Kyowa Kirin - Consultancy (Includes expert testimony); Secura Bio - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Janssen-Cilag - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony)